JP2020111602A5 - - Google Patents

Download PDF

Info

Publication number
JP2020111602A5
JP2020111602A5 JP2020068792A JP2020068792A JP2020111602A5 JP 2020111602 A5 JP2020111602 A5 JP 2020111602A5 JP 2020068792 A JP2020068792 A JP 2020068792A JP 2020068792 A JP2020068792 A JP 2020068792A JP 2020111602 A5 JP2020111602 A5 JP 2020111602A5
Authority
JP
Japan
Prior art keywords
methyl
pyridin
oxy
carbamoyl
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020068792A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020111602A (ja
JP6985448B2 (ja
Filing date
Publication date
Priority claimed from JP2018126337A external-priority patent/JP2018184416A/ja
Application filed filed Critical
Publication of JP2020111602A publication Critical patent/JP2020111602A/ja
Publication of JP2020111602A5 publication Critical patent/JP2020111602A5/ja
Application granted granted Critical
Publication of JP6985448B2 publication Critical patent/JP6985448B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020068792A 2013-03-15 2020-04-07 抗がんおよび抗増殖活性を示すn−アシル−n’−(ピリジン−2−イル)尿素および類似体 Active JP6985448B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361789971P 2013-03-15 2013-03-15
US61/789,971 2013-03-15
JP2018126337A JP2018184416A (ja) 2013-03-15 2018-07-02 抗がんおよび抗増殖活性を示すn−アシル−n’−(ピリジン−2−イル)尿素および類似体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018126337A Division JP2018184416A (ja) 2013-03-15 2018-07-02 抗がんおよび抗増殖活性を示すn−アシル−n’−(ピリジン−2−イル)尿素および類似体

Publications (3)

Publication Number Publication Date
JP2020111602A JP2020111602A (ja) 2020-07-27
JP2020111602A5 true JP2020111602A5 (enExample) 2021-04-22
JP6985448B2 JP6985448B2 (ja) 2021-12-22

Family

ID=51529946

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016503187A Active JP6364472B2 (ja) 2013-03-15 2014-03-14 抗がんおよび抗増殖活性を示すn−アシル−n’−(ピリジン−2−イル)尿素および類似体
JP2018126337A Pending JP2018184416A (ja) 2013-03-15 2018-07-02 抗がんおよび抗増殖活性を示すn−アシル−n’−(ピリジン−2−イル)尿素および類似体
JP2020068792A Active JP6985448B2 (ja) 2013-03-15 2020-04-07 抗がんおよび抗増殖活性を示すn−アシル−n’−(ピリジン−2−イル)尿素および類似体

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2016503187A Active JP6364472B2 (ja) 2013-03-15 2014-03-14 抗がんおよび抗増殖活性を示すn−アシル−n’−(ピリジン−2−イル)尿素および類似体
JP2018126337A Pending JP2018184416A (ja) 2013-03-15 2018-07-02 抗がんおよび抗増殖活性を示すn−アシル−n’−(ピリジン−2−イル)尿素および類似体

Country Status (15)

Country Link
US (1) US9382228B2 (enExample)
EP (1) EP2968287B1 (enExample)
JP (3) JP6364472B2 (enExample)
KR (2) KR102386952B1 (enExample)
CN (3) CN110563700A (enExample)
AU (2) AU2014233414B2 (enExample)
BR (1) BR112015022263B1 (enExample)
CA (1) CA2903288C (enExample)
ES (1) ES2817902T3 (enExample)
IL (2) IL241523B (enExample)
MX (2) MX366429B (enExample)
PH (2) PH12020550201A1 (enExample)
RU (1) RU2769607C2 (enExample)
SG (1) SG11201508532VA (enExample)
WO (1) WO2014145028A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5335056B2 (ja) 2011-11-16 2013-11-06 住友電気工業株式会社 ボルト用アルミニウム合金線及びボルト並びにそれらの製造方法
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CN110563700A (zh) * 2013-03-15 2019-12-13 德西费拉制药有限责任公司 展现抗癌和抗增殖活性的n-酰基-n′-(吡啶-2-基)脲及类似物
TWI747873B (zh) 2016-02-01 2021-12-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
KR101691954B1 (ko) 2016-04-26 2017-01-02 고려대학교 산학협력단 신규 n-아실유레아 유도체 및 이를 함유하는 심혈관질환의 예방 또는 치료용 조성물
KR102374012B1 (ko) * 2017-05-24 2022-03-14 아비스코 테라퓨틱스 컴퍼니 리미티드 N-(아자릴)시클로락탐-1-카르복사미드 유도체 및 합성법과 그 용법
CN110461849B (zh) * 2017-06-19 2020-09-01 上海和誉生物医药科技有限公司 一种csf1r抑制剂及其制备方法和应用
CA3073611A1 (en) * 2017-08-24 2019-02-28 Merck Patent Gmbh Boronic acid derivatives
CN109776401A (zh) * 2017-11-14 2019-05-21 成都博腾药业有限公司 一种制备6-氯-5-三氟甲基-2-氨基吡啶的方法
EP3746059B1 (en) 2018-01-31 2026-03-04 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of gastrointestinal stromal tumors
AU2019216351B2 (en) 2018-01-31 2024-07-25 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
CN110845476B (zh) * 2018-08-21 2022-11-18 上海和誉生物医药科技有限公司 一种高选择性csf1r抑制剂、其制备方法和在药学上的应用
KR20210119411A (ko) 2018-12-28 2021-10-05 데시페라 파마슈티칼스, 엘엘씨. 암 치료에 사용하기 위한 csf1r 억제제
CN113692304B (zh) * 2019-02-06 2025-03-18 礼来公司 作为kcnq增强剂的1-((2-(2,2,2-三氟乙氧基)吡啶-4-基)甲基)脲衍生物
WO2020185812A1 (en) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
EP3966207B1 (en) 2019-05-10 2023-11-01 Deciphera Pharmaceuticals, LLC Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
EP3966206B1 (en) 2019-05-10 2023-08-09 Deciphera Pharmaceuticals, LLC Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
JP7626722B2 (ja) 2019-06-17 2025-02-04 デシフェラ・ファーマシューティカルズ,エルエルシー アミノピリミジンアミドオートファジー阻害剤およびその使用方法
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
FI4013412T3 (fi) 2019-08-12 2026-03-24 Deciphera Pharmaceuticals Llc Ripretinibi ruoansulatuskanavan stroomakasvaimien hoitoon
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
PL4084779T3 (pl) 2019-12-30 2025-02-24 Deciphera Pharmaceuticals, Llc Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika
JP2023549540A (ja) 2020-11-18 2023-11-27 デシフェラ・ファーマシューティカルズ,エルエルシー Gcn2およびperkキナーゼ阻害剤およびその使用方法
CN115385896B (zh) * 2021-05-24 2024-11-15 上海和誉生物医药科技有限公司 一种csf-1r抑制剂中间体或其酸式盐的制备方法
TWI912522B (zh) * 2021-05-24 2026-01-21 大陸商上海和譽生物醫藥科技有限公司 一種結晶型csf-1r抑制劑酸式鹽及其製備方法和應用
PE20250609A1 (es) 2021-12-03 2025-02-26 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos
US12319655B2 (en) 2021-12-09 2025-06-03 Deciphera Pharmaceuticals, Llc RAF kinase inhibitors and methods of use thereof
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
WO2025122942A1 (en) 2023-12-08 2025-06-12 Deciphera Pharmaceuticals, Llc Solid state forms of a kinase inhibitor
US20250205161A1 (en) 2023-12-08 2025-06-26 Deciphera Pharmaceuticals, Llc Formulations of vimseltinib
WO2025231106A1 (en) 2024-05-01 2025-11-06 Deciphera Pharmaceuticals, Llc Csf-1r inhibitors and methods of use thereof
WO2025231105A1 (en) 2024-05-01 2025-11-06 Deciphera Pharmaceuticals, Llc Processes of making csf-1r inhibitors and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA861446B (en) * 1985-03-01 1986-10-29 Duphar Int Res Benzoyl urea derivatives having anti-tumor activity
CA2454538A1 (en) * 2001-06-22 2003-01-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
CA2755268C (en) * 2005-11-15 2013-12-31 Array Biopharma, Inc. Erbb inhibitors
WO2008046216A1 (en) * 2006-10-18 2008-04-24 Methylgene, Inc. Kinase inhibitors and uses thereof
WO2008079291A2 (en) * 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
CN102256493A (zh) * 2008-10-29 2011-11-23 迪赛孚尔制药有限公司 表现出抗癌活性和抗增殖活性的环丙烷酰胺及其类似物
CN110563700A (zh) * 2013-03-15 2019-12-13 德西费拉制药有限责任公司 展现抗癌和抗增殖活性的n-酰基-n′-(吡啶-2-基)脲及类似物

Similar Documents

Publication Publication Date Title
JP2016516724A5 (enExample)
AU2018236691B2 (en) N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
RU2454405C2 (ru) Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина
RU2012126989A (ru) 2-амино-5,5-дифтор-5,6-дигидро-4н-оксазины в качестве ингибиторов васе 1 и(или) васе 2
CN109071488A (zh) 取代的1,2,3-三唑作为nr2b-选择性nmda调节剂
HRP20212000T1 (hr) Aminotriazolopiridini kao inhibitori kinaze
JP6964576B2 (ja) 置換4−アザインドール及びglun2b受容体調節因子としてのそれらの使用
IL276998B2 (en) Piperidinyl-3-(aryloxy)propanamides and propanoates
JP2017512794A5 (enExample)
JP2009531309A5 (enExample)
JP2016523911A5 (enExample)
JP2010512337A5 (enExample)
JP2015524837A5 (enExample)
CA2494091A1 (en) Substituted furo [2,3-b| pyridine derivatives
JP2004506718A5 (enExample)
RU2016108753A (ru) Ингибиторы ферментов
RU2013125337A (ru) Производные триазола и их применение при неврологических заболеваниях
RU2015100942A (ru) Производное пиперидинилпиразолпиридина
RU2018131766A (ru) 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета
JP2008509955A5 (enExample)
IL296790A (en) Amide compounds and their uses
RU2013125338A (ru) Производные триазола в качестве лигандов рецепторов гамк
RU2015115360A (ru) Новые анти-инвазивные соединения
JP2020531486A5 (enExample)
JP2020531487A5 (enExample)